title: Allogeneic versus autologous bone marrow transplantation (BMT) versus intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase III trial (AML8 A). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
authors.affiliation: Service d'Hématologie, Hotel Dieu, Paris, France.
authors.forename: R
authors.initials: R
authors.lastname: Zittoun
authors.forename: F
authors.initials: F
authors.lastname: Mandelli
authors.forename: R
authors.initials: R
authors.lastname: Willemze
authors.forename: T
authors.initials: T
authors.lastname: de Witte
authors.forename: S
authors.initials: S
authors.lastname: Tura
authors.forename: P R
authors.initials: PR
authors.lastname: Ferrini
authors.forename: P
authors.initials: P
authors.lastname: Stryckmans
authors.forename: C
authors.initials: C
authors.lastname: Gattringer
authors.forename: M C
authors.initials: MC
authors.lastname: Petti
authors.forename: G
authors.initials: G
authors.lastname: Solbu
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*; D008875:Middle Aged; D012074:Remission Induction; D016019:Survival Analysis; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
chemical_list: D003561:Cytarabine; D003630:Daunorubicin